Asia Pacific Thrombosis and Hemostasis Biomarkers Market Size, Share, and COVID-19 Impact Analysis, By Test Type (D-dimer, Anti-Thrombin III, Plasminogen, Post-Thrombin (PT) test, and Others), By Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular Coagulation (DIC), and Others), and Asia Pacific Thrombosis and Hemostasis Biomarkers Market Insights, Industry Trend, Forecasts to 2035

Asia Pacific Thrombosis and Hemostasis Biomarkers Market Size Insights Forecasts to 2035

• The Asia Pacific Thrombosis and Hemostasis Biomarkers Market Size was estimated at USD 1.18 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 7.26% from 2025 to 2035
• The Asia Pacific Thrombosis and Hemostasis Biomarkers Market Size is Expected to Reach USD 2.55 Billion by 2035

According to a Research Report Published by Spherical Insights & Consulting, The Asia Pacific Thrombosis and Hemostasis Biomarkers Market Size is anticipated to Reach USD 2.55 Billion by 2035, Growing at a CAGR of 7.26% from 2025 to 2035. The growing prevalence of chronic & thrombotic disorders, like venous thromboembolism (VTE) and cancer, is driving the demand for diagnostic tools, thereby driving the thrombosis and hemostasis biomarkers market in the Asia Pacific region.

Market Overview

The Asia Pacific thrombosis and hemostasis biomarkers market refers to the specialized segment of the life sciences industry emphasizing the development and sales of biological markers used for detecting, assessing risk, and monitoring conditions such as excessive or abnormal blood clot formation (thrombosis) and the body’s clotting process (hemostasis). Thrombosis and hemostasis biomarkers are used for diagnosis and assessing the risk of thrombotic events in cases of pancreatic cancer. Personalized medicine treatment plans for individuals with unique genetic makeup and medical history, with funded research into the arena for transforming heart treatments, are providing growth opportunities in the thrombosis and hemostasis biomarkers market.   

Report Coverage

This research report categorizes the market for the Asia Pacific thrombosis and hemostasis biomarkers market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific thrombosis and hemostasis biomarkers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific thrombosis and hemostasis biomarkers market.

Driving Factors

The predictions related to the risk of venous thromboembolism (VTE) and monitoring treatment response are driving the adoption of biomarker products, which ultimately drive the thrombosis and hemostasis biomarkers market. Further, the growing demand for biomarkers for assessing and monitoring the surging use of hemostasis analyzers and thrombosis reagents, driving sales, significantly propels market growth. The development of personalized treatment plans by healthcare providers for more safety and effectiveness is contributing to driving the market demand for thrombosis and hemostasis biomarkers.

Restraining Factors

The increased cost of biomarker testing and limited awareness in emerging markets are challenging the thrombosis and hemostasis biomarkers market. Further, the limited specificity and sensitivity of biomarkers like fibrin degradation products are restraining the market.

Market Segmentation

The Asia Pacific Thrombosis and Hemostasis Biomarkers market share is classified into test type and application.

• The post-thrombin (PT) test segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific thrombosis and hemostasis biomarkers market is segmented by test type into D-dimer, anti-thrombin III, plasminogen, post-thrombin (PT) test, and others. Among these, the post-thrombin (PT) test segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The post-thrombin (PT) test includes the measurement of the time taken for blood to clot after an enzyme called thrombin is added. The increasing prevalence of coagulation disorders, along with an increasing number of surgical procedures and effective anticoagulation monitoring, is driving the market demand.

• The deep vein thrombosis (DVT) segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific Thrombosis and Hemostasis Biomarkers market is segmented by application into deep vein thrombosis (DVT), pulmonary embolism (PE), disseminated intravascular coagulation (DIC), and others. Among these, the deep vein thrombosis (DVT) segment held the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. Deep vein thrombosis is a pulmonary embolism, having high morbidity and mortality, especially in hospitalized patients. The growing emphasis on developing advanced anticoagulants and thrombolytic therapies is contributing to driving market growth in the deep vein thrombosis (DVT) segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific thrombosis and hemostasis biomarkers market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Siemens Healthineers AG (Siemens AG)
• Abbott Laboratories
• BioMérieux S.A.
• Horiba Ltd.
• QuidelOrtho Corporation
• Werfen, S.A.
• Others

Recent Developments:

• In October 2021, Trivitron Healthcare, a leading medical devices company has announced the launch of a new line of Coagulation Analyzer products manufactured by Diagon Ltd.
• In February 2021, Siemens Healthineers and Sysmex Corporation announced the renewal of the companies long standing global supply, distributorship, sales, and service agreement for a broad portfolio of hemostasis products, including a multi-year extension.
• In July 2020, Sysmex launched new products in the hemostasis field: the automated blood coagulation analyzers CN-6500/CN-3500. These new offerings from Sysmex come with a measuring unit using the chemiluminescence enzyme immunoassay methodology (CLEIA).

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific Thrombosis and Hemostasis Biomarkers Market based on the below-mentioned segments:

Asia Pacific Thrombosis and Hemostasis Biomarkers Market, By Test Type

• D-dimer
• Anti-Thrombin III
• Plasminogen
• Post-Thrombin (PT) test
• Others

Asia Pacific Thrombosis and Hemostasis Biomarkers Market, By Application

• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Disseminated Intravascular Coagulation (DIC)
• Others